Boxborough, MA – Vibalogics, a contract development and manufacturing organization (CDMO), and an Ampersand Capital Partners portfolio company, focused on the manufacture of oncolytic viruses, viral vaccines and gene therapies, has today announced that it will be acquired by top global CDMO Recipharm AB (Stockholm, Sweden).
The acquisition comes as part of a series of deals made recently by Recipharm, including the acquisition of GenIbet Biopharmaceuticals S.A. (Oeiras, Portugal) and Arranta Bio (Watertown, MA), as it sets out to further expand its service offering into novel and advanced biological modalities.
Vibalogics virotherapy CDMO business has been rapidly growing along with global biopharmaceutical industry demand for the manufacture of BSL-2 live viruses and viral vectors. Ongoing capital investment, as part of the 2019 acquisition by Ampersand Capital Partners has accelerated the company’s growth strategy and has driven future scalability. Recent capital expansions in the US and Germany have included a new 118,000 ft2 US global headquarters and clinical-through-commercial capable virus production facility in Boxborough, MA (operational Q4 2021), and expansion of the company’s existing 100,000 ft2 (9,400m2) Cuxhaven, Germany facility.
Substantial growth and development in recent years has positioned Vibalogics for full product lifecycle support of its clients. The company’s infrastructure improvements have been coupled with strengthened operations and expansion of its global executive leadership team, including CEO, Tom Hochuli (Lonza Houston Cell & Gene Therapy Division), CCO, Roger Lias PhD (CEO, Stelis Biopharma Pvt. Ltd., Avid Bioservices Inc.), CFO, Michael DiMeo (Thermo Fisher Scientific), promotion of Vibalogics long-time veteran Kai Lipinski PhD to CSO, formation of the Scientific Advisory Board, and expansion to over 200 employees projected by year end. Vibalogics will continue to operate in its current capacity, but will further leverage company synergies driven through the network capabilities of GenIbet, Arranta Bio, and Recipharm.
Stefan Beyer, President, and Managing Director (former CEO, ‘06-19), commented “We at Vibalogics are all so very pleased to become a part of the global Recipharm portfolio. Our ability to leverage additional capabilities and resources of the combined organization will be of tremendous value to our clients, who will benefit from our strengthened platform with additional opportunity for plasmid and starting cell and virus bank production, platform analytical capabilities, and expanded drug substance and fill finish options through the new global network established under Recipharm.”
Marina Pellón-Consunji, Partner of Ampersand Capital Partners, added, “With decades of expertise in the development and manufacturing of live viruses and viral vectors and clinical-through-commercial virus manufacturing capabilities in Europe and the United States, the team at Vibalogics is well-positioned to service the full product lifecycle of virotherapy customers. We are excited for Vibalogics’ acquisition by Recipharm and believe this is a powerful combination to better serve customers worldwide in the development and manufacturing of life-changing virotherapies.”
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. www.recipharm.com
Media Contacts
For further information on Vibalogics, images and interview opportunities, please contact ramarketing: | +44 (0)7972471903 | Twitter: @ramarketingpr | Facebook: /ramarketingpr | Linkedin: /ramarketing
For further information, images and interview opportunities, please contact Lara Lovenbury at ramarketing: lara@ramarketingpr.com | +44 (0)7972471903 | ramarketingpr.com | Twitter: @ramarketingpr | Facebook: /ramarketingpr | Linkedin: /ramarketing
